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Cardiac Resynchronization Therapy Using Quadripolar Versus
Non-Quadripolar Left Ventricular Leads Programmed to Biventricular
Pacing With Single-Site Left Ventricular Pacing: Impact on Survival
and Heart Failure Hospitalization
Francisco Leyva, MD, FACC; Abbasin Zegard, MB, ChB; Tian Qiu, PhD; Edmund Acquaye, MB, ChB; Gaetano Ferrante, BSc;
Jamie Walton, BSc; Howard Marshall, MD
Background-—In cardiac resynchronization therapy (CRT), quadripolar (QUAD) left ventricular (LV) leads are less prone to
postoperative complications than non-QUAD leads. Some studies have suggested better clinical outcomes.
Methods and Results-—Clinical events were assessed in 847 patients after CRT-pacing or CRT-deﬁbrillation using either QUAD
(n=287) or non-QUAD (n=560), programmed to single-site site LV pacing. Over a follow-up period of 3.2 years (median
[interquartile range, 1.90–5.0]), QUAD was associated with a lower total mortality (adjusted hazard ratio [aHR]: 0.32, 95%
conﬁdence interval [CI], 0.20–0.52), cardiac mortality (aHR: 0.36, 95% CI, 0.20–0.65), and heart failure (HF) hospitalization (aHR:
0.62, 95% CI, 0.39–0.99), after adjustment for age, sex, New York Heart Association class, HF etiology, device type (CRT-pacing or
CRT-deﬁbrillation), comorbidities, atrial rhythm, medication, left ventricular ejection fraction, and creatinine. Death from pump
failure was lower with QUAD (aHR: 0.33; 95% CI, 0.18–0.62), but no group differences emerged with respect to sudden cardiac
death. There were no differences in implant-related complications. Re-interventions for LV displacement or phrenic nerve
stimulation, which were lower with QUAD, predicted total mortality (aHR: 1.68, 95% CI, 1.11–2.54), cardiac mortality (aHR: 2.61,
95% CI, 1.66–4.11) and HF hospitalization (aHR: 2.09, 95% CI, 1.22–3.58).
Conclusions-—CRT using QUAD, programmed to biventricular pacing with single-site LV pacing, is associated with a lower total
mortality, cardiac mortality, and HF hospitalization. These trends were observed for both CRT-deﬁbrillation and CRT-pacing, after
adjustment for HF cause and other confounders. Re-intervention for LV lead displacement or phrenic nerve stimulation was
associated with worse outcomes. ( J Am Heart Assoc. 2017;6:e007026. DOI: 10.1161/JAHA.117.007026.)
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C ardiac resynchronization therapy (CRT), with CRT-deﬁ-brillation (CRT-D) or without (CRT-pacing [CRT-P]) deﬁb-
rillation, is a standard treatment for selected patients with
heart failure (HF) with severe left ventricular (LV) dysfunction
and a wide QRS complex.1 Since the ﬁrst transvenous CRT
implantations were undertaken in the 1990s,2,3
improvements in delivery catheter and LV lead design, as
well as implantation techniques using venoplasty and snaring,
have helped to improve implantation success. Prominent
among the challenges still encountered at implantation and
thereafter is achieving acceptable LV pacing thresholds
without phrenic nerve stimulation (PNS).4 Deactivation of
the LV lead mainly occurs as a result of LV lead displacement
which, in studies using unipolar and bipolar leads, occurs
more frequently than with atrial or right ventricular leads.5–9
Since their launch in 2010, quadripolar LV leads (QUAD)
have been considered by implanters as a “game-changer,”
even before robust clinical evidence emerged in their favor.
Observational studies and a randomized, controlled trial10
have since shown that QUAD is associated with higher
implant success rates and lower rates of re-interventions for
LV lead displacement or PNS.11,12
Some observational studies have suggested that CRT-D
using QUAD programmed to single-site LV pacing also
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improves survival.12–14 These ﬁndings, however, are not
consistent,15 and there is uncertainty as to whether they also
apply to CRT-P. Moreover, the possible inﬂuence of HF
etiology and the effects of QUAD on HF hospitalization and
mode of death remain largely unexplored.
Methods
This is a nonrandomized, retrospective, observational study
comparing clinical outcomes of patients undergoing CRT-D
and CRT-P device implantation using unipolar, bipolar, and
quadripolar leads in a single center (Queen Elizabeth Hospital,
Birmingham, United Kingdom) from February 2010 to January
2017. The study was approved by the Clinical Audit Depart-
ment at the Queen Elizabeth Hospital, which does not require
informed consent for audit of clinical care delivery. The study
conforms to the Declaration of Helsinki.
Implantation
Device implantation was undertaken using standard tech-
niques with patients under local anesthesia and intravenous
sedation. Access was gained via subclavian, axillary, and
cephalic veins. The LV pacing site was chosen by the
implanter on the basis of lead stability, absence of PNS, and
adequate pacing parameters. An implant was considered a
failure in the event of failure to deploy all desired leads and
device at the index procedure. The ﬁrst QUAD was implanted
in February 2010. The following QUAD leads were used:
Quartet 1458Q (St. Jude Medical, Sylmar, CA), Attain
Performa (Medtronic Inc, Minneapolis, MN), and Acuity X4
(Boston Scientiﬁc, Marlborough, MA). The choice of vector
was made at implantation and was made on the basis of
presence or absence of PNS.
Follow-Up
Patients were followed up in dedicated device therapy clinics.
Before 2013, patients underwent systematic echocardio-
graphic optimization. To this end, patients in sinus rhythm
underwent transmitral Doppler-directed optimization of atri-
oventricular delay using an iterative technique before dis-
charge and at every scheduled visit thereafter. In patients with
sinus rhythm, atrial pacing was set at 60 beats/min, and the
pacing mode was set to DDDR with an interventricular delay
of 0 to 4 ms, according to the manufacturer. In patients with
permanent atrial ﬁbrillation, right ventricular and LV leads
were implanted and a CRT generator was used, plugging the
atrial port and programming the generator to a ventricular
triggered mode. In patients with uncontrolled atrial ﬁbrillation
despite medical therapy with suboptimal biventricular pacing
capture (<98%), atrioventricular junction ablation was under-
taken, according to the individual clinician’s decision. After
2013, echocardiographic optimization was only undertaken in
symptomatic nonresponders.
End Points
The primary end point was total mortality, which included
cardiac transplantation. Secondary end points included
cardiac mortality and unplanned HF hospitalization. The
ﬁrst event was included in the analysis. With respect to
mode of death, sudden cardiac death was deﬁned as a
“natural, unexpected death due to cardiac causes, heralded
by an abrupt loss of consciousness within 1 hour of the
onset of acute symptoms,”16 whereas death from pump
failure was deﬁned as “death after a period of clinical
deterioration in signs and symptoms of heart failure despite
medical treatment”17 or cardiac transplantation. Mortality
data were collected through medical records every
3 months by investigators who were blinded to all other
patient data. Mortality and event data were collected by
separate investigators who were blinded to all other data,
except patient identiﬁers.
Statistical Analysis
In preliminary analyses, no differences in outcomes emerged
between unipolar and bipolar LV leads (data not shown). On
this basis, the latter were classiﬁed as “non-QUAD” in
statistical analyses. Normality was tested using the Shapiro–
Wilk test. Continuous variables are expressed as mean (SD)
Clinical Perspective
What Is New?
• In this nonrandomized, retrospective, observational study of
patients undergoing cardiac resynchronization therapy (CRT)
with quadripolar (QUAD) and non-QUAD left ventricular
leads, programmed to biventricular, single-site left ventric-
ular pacing, QUAD was associated with a lower total
mortality, cardiac mortality, and heart failure hospitalization.
• These beneﬁts were observed after both CRT-deﬁbrillation
and CRT-pacing, after adjustment for heart failure etiology.
• Re-interventions for left ventricular displacement or phrenic
nerve stimulation, which were lower with QUAD, were
associated with worse outcomes.
What Are the Clinical Implications?
• The markedly better outcomes after CRT observed with
QUAD supports their preferential use over non-QUAD in
clinical practice.
• The relative beneﬁts of CRT-deﬁbrillation over CRT-pacing
requires further evaluation in the QUAD era.
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and compared using the Student t test. Categorical variables
were compared using the v2 tests. Kaplan–Meier curves and
the log-rank tests were used to assess observed cumulative
survival and to test for differences in survival, respectively.
Cox proportional hazard models were used to compare hazard
rates of subgroups. Variables reaching a P<0.10 on univari-
able analyses were entered in multivariable models, and
further backward elimination was applied for the ﬁnal
multivariable models. Confounders included in ﬁnal models
were the following: quadripolar lead, sex (male), age at
implantation, New York Heart Association (NYHA) class,
creatinine, QRS duration, and medication of angiotensin-
converting enzyme inhibitors/angiotensin receptor blockers.
Proportionality hypotheses were veriﬁed by visual examina-
tion of log (survival) graphs to ensure parallel slopes, and
by examining Schoenfeld residuals. Statistical analyses
were undertaken using Stata 14 (StataCorp, Houston, TX).
A 2-sided P≤0.05 was considered statistically signiﬁcant.
Results
Baseline Characteristics
Over the study period of 6.9 years, 847 patients underwent
CRT (CRT-D: 436 [51.5%]; CRT-P: 411 [48.5%]), using QUAD
(287 [33.9%]), unipolar (63 [7.43%]), or bipolar (497 [58.7%])
leads. Implantations using unipolar and bipolar leads were
classiﬁed as non-QUAD. As shown in Table 1, the groups were
well matched for age, sex, cause of cardiomyopathy, comor-
bidities, proportion of upgrades from pacemaker, atrial rhythm
(sinus rhythm or atrial ﬁbrillation), QRS morphology, QRS
duration, and left ventricular ejection fraction. Compared with
the non-QUAD group, QUAD were more likely to be in NYHA
class I and II (P<0.001) and to undergo CRT-D (62.0% versus
46.1%, P<0.001). In addition, QUAD had a lower uptake of
loop diuretics (P=0.003) and a higher uptake of b-blockers
(P=0.004).
Total Mortality
Over a follow-up period of 3.2 years (median [interquartile
range,1.90 to 5.0; 1.8 years [interquartile range, 1.0–2.6] for
QUAD; 4.7 years [interquartile range, 3.4–5.7] for non-QUAD),
QUAD was associated with a lower total mortality in Kaplan–
Meier survival analyses (log rank P<0.001, Figure 1). The
annualized total mortality rate was 3.6% (n=19) for QUAD and
10.9% (n=218) for non-QUAD. Event rates are shown in
Table 2. Univariable Cox proportional hazards analyses are
shown in Table 3. In multivariable analyses (Table 4), QUAD
was associated with a lower mortality (adjusted hazard ratio
[aHR]: 0.32, 95% conﬁdence interval [CI], 0.20–0.52), after
adjustment for age, sex, NYHA class, and creatinine. Other
confounders failed to reach signiﬁcance in multivariable
models. In order to exclude a possible time-related bias, we
explored whether date of implant emerged as a predictor of
Table 1. Characteristics of the Study Group
QUAD Non-QUAD P Value*
N 287 560
Sex (male), n (%) 209 (72.8) 398 (71.1) 0.592
Age, y 72.512.2 73.211.3 0.517
NYHA class, n (%)
I 40 (14.3) 32 (5.8) <0.001
II 87 (31.1) 66 (11.9)
III 148 (52.9) 419 (75.5)
IV 5 (1.79) 38 (6.9)
Cause of cardiomyopathy, n (%)
Ischemic 151 (52.6) 279 (49.8) 0.442
Nonischemic 136 (47.4) 281 (50.2)
Device type, n (%)
CRT-D 178 (62.0) 258 (46.1) <0.001
CRT-P 109 (38.0) 302 (53.9)
Comorbidities, n (%)
Diabetes mellitus 80 (28.1) 127 (22.9) 0.099
Hypertension 87 (30.5) 165 (29.7) 0.811
CABG 48 (16.7) 102 (18.2) 0.591
Upgrade from pacemaker 56 (19.5) 119 (21.6) 0.554
ECG variables
Sinus rhythm, n (%) 195 (67.9) 356 (63.6) 0.206
Atrial fibrillation, n (%)† 92 (32.1) 204 (36.4)
QRS morphology
(LBBB), n (%)
228 (79.4) 438 (78.2) 0.680
QRS duration, ms‡ 152.624.0 152.425.0 0.896
Medication, n (%)
Loop diuretics 274 (95.5) 553 (98.8) 0.003
ACEIs/ARA 257 (89.6) 489 (87.3) 0.344
b-Blockers 227 (79.1) 391 (69.2) 0.004
MRA 124 (43.2) 244 (43.6) 0.919
LVEF, % 24.99.1 25.811.2 0.249
Creatinine, lmol/L§ 106 (89–129) 104 (87–132) 0.727
Variables are expressed as meanSD, unless indicated otherwise. ACEI indicates
angiotensin-converting enzyme inhibitors; ARA, angiotensin receptor blockers; CABG,
coronary artery bypass grafting; CRT-D, cardiac resynchronization therapy-deﬁbrillation;
CRT-P, cardiac resynchronization therapy-pacing; LBBB, left bundle branch block; LVEF,
left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonists; NYHA,
New York Heart Association; QUAD, quadripolar left ventricular lead.
*Refers to differences between the groups from ANOVA for continuous variables and
from v2 tests for categorical variables.
†Includes permanent, persistent, and paroxysmal atrial ﬁbrillation.
‡Excludes upgrades to pacemaker.
§Log-transformed for statistical analyses.
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total mortality. In multivariable Cox proportional hazards
analysis, date of implant did not predict total mortality (HR:
1.46, 95% CI, 0.95–2.26).
Cardiac Mortality
The annualized cardiac mortality rate was 2.40% (n=13) for
QUAD and 6.0% (n=136) for non-QUAD (Table 2). In Kaplan–
Meier survival analyses, QUAD was associated with a lower
cardiac mortality (log rank P<0.001, Figure 1). In multivariable
analyses (Table 4), QUAD was associated with a lower cardiac
mortality (aHR: 0.36, 95% CI, 0.20–0.65), after adjustment for
known confounders.
HF Hospitalization
The annualized HF hospitalization rate was 4.40% for QUAD
(n=22) and 5.6% (n=104) for non-QUAD (Table 2). In
Kaplan–Meier survival analyses, QUAD was associated with
a lower risk of HF hospitalization (log rank P=0.028,
Figure 1). In multivariable analyses (Table 4), QUAD was
associated with a lower risk of HF hospitalization (aHR:
0.62, 95% CI, 0.39–0.99), after adjustment for potential
confounders.
QUAD and Device Type
In univariable (Table 3) and mutivariable (Table 4) analyses,
CRT-D did not emerge as a predictor of any end point.
Separate analyses according to device type were also
undertaken. As shown in Figure 2, QUAD was superior to
non-QUAD with respect to all end points in Kaplan–Meier
survival analyses. In univariable analyses including CRT-D
patients only, QUAD was superior to non-QUAD with respect
to total mortality (HR: 0.44, 95% CI, 0.25–0.76) and cardiac
mortality (HR: 0.43, 95% CI, 0.22–0.85). A lower, albeit
nonsigniﬁcant reduction with QUAD was observed in HF
hospitalization (HR: 0.54, 95% CI, 0.29–1.01). In univariable
analyses including CRT-P patients only, QUAD was superior to
non-QUAD with respect to total mortality (HR: 0.16, 95% CI,
0.06–0.45) and cardiac mortality (HR: 0.23, 95% CI, 0.07–
logrank P = .0280.20
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Figure 1. Clinical outcomes according to lead type. Kaplan–
Meier survival curves for clinical outcomes according to device
and lead type. HF indicates heart failure; QUAD, quadripolar
lead.
Table 2. Event Rates According to Lead Type
QUAD (n=287)
Non-QUAD
(n=560)
n %* n %*
Total mortality 19 3.6 218 10.9
Cardiac mortality 13 2.4 136 6.0
HF hospitalization 22 4.4 104 5.6
Death from pump failure 11 2.1 122 5.4
SCD 2 0.4 13 0.6
HF indicates heart failure; QUAD, quadripolar left ventricular lead; SCD, sudden cardiac
death.
*Data are expressed in terms of annualized event rates.
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0.73), but no differences emerged in HF hospitalization (HR:
0.67, 95% CI, 0.32–1.37).
Mode of Death
Over the follow-up period, there were 11/287 (3.83%) deaths
because of pump failure with QUAD and 122/558 (21.8%) with
non-QUAD. There were 2/287 (0.70%) sudden cardiac deaths
with QUAD and 13/560 (2.32%) with non-QUAD. Noncardiac
deaths accounted for 3/287 (1.04%) deaths with QUAD and
42/560 (7.5%) deaths with non-QUAD. The cause and mode of
death was unknown in 3 (1.04%) patients with QUAD and in 40
(7.14%) patients with non-QUAD. Excluding these patients,
QUAD was associated with a lower mortality from pump failure
(log rank P<0.001; aHR: 0.33; 95% CI, 0.18–0.62), but no
differences emerged with respect to sudden cardiac death
(aHR: 0.58; 95% CI, 0.13–2.68, Figure 3).
Implantation
There were 856 ﬁrst attempts at CRT device implantation,
833 (97.3%) of which were successful at the ﬁrst attempt and
847 (98.9%) after ≥1 attempts. Re-interventions for LV
displacement or PNS were lower with QUAD than with non-
QUAD (Table 5, Figure 4). In univariable analyses, re-inter-
ventions for LV displacement or PNS predicted total mortality
(aHR: 1.68, 95% CI, 1.11–2.54), cardiac mortality (aHR: 2.61,
95% CI, 1.66–4.11), and HF hospitalization (aHR: 2.09, 95%
CI, 1.22–3.58).
Other Complications
As shown in Table 5, implant-related complications were
similar for QUAD and non-QUAD (odds ratio: 1.30, 95% CI,
0.71–2.36). A total of 8 extractions for system infection were
undertaken within 1 year of implantation (QUAD: 3 (1.05%);
Table 3. Univariable Cox Proportional Hazards Analyses of Baseline Variables in Relation to Clinical Outcomes
Total Mortality Cardiac Mortality HF Hospitalization
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Lead type (QUAD) 0.31 0.19 0.49 <0.001 0.35 0.20 0.63 <0.001 0.60 0.37 0.95 0.030
Sex (male) 1.76 1.28 2.42 0.001 1.99 1.30 3.04 0.001 1.23 0.82 1.84 0.309
Age 1.04 1.02 1.05 <0.001 1.02 1.00 1.03 0.029 1.03 1.01 1.04 0.004
NYHA class
III 1.50 1.04 2.18 0.031 1.41 0.90 2.21 0.138 1.25 0.80 1.94 0.329
IV 3.74 2.25 6.21 <0.001 2.40 1.25 4.61 0.009 1.24 0.51 3.03 0.634
Cause (ischemic) 1.23 0.95 1.59 0.112 1.21 0.88 1.67 0.249 1.31 0.92 1.87 0.130
Device type (CRT-D) 0.81 0.63 1.04 0.100 0.96 0.70 1.33 0.810 0.98 0.69 1.39 0.922
Comorbidities
Diabetes mellitus 1.33 1.00 1.77 0.050 1.57 1.11 2.22 0.010 1.48 1.02 2.16 0.042
Hypertension 1.10 0.83 1.45 0.509 0.91 0.63 1.31 0.620 0.96 0.65 1.41 0.820
CABG 1.16 0.85 1.60 0.352 1.05 0.70 1.59 0.801 1.04 0.66 1.63 0.872
ECG variables
Atrial fibrillation 1.36 1.05 1.76 0.019 1.26 0.91 1.74 0.171 0.94 0.65 1.36 0.741
QRS morphology (LBBB) 0.81 0.60 1.09 0.161 0.71 0.50 1.02 0.064 0.57 0.39 0.84 0.004
QRS duration, ms 1.00 0.99 1.00 0.115 0.99 0.99 1.00 0.041 0.99 0.98 0.99 <0.001
Medication
Loop diuretics 1.38 0.44 4.32 0.578 2.73 0.38 19.51 0.317
ACEIs/ARA 0.54 0.39 0.76 <0.001 0.52 0.35 0.79 0.002 1.28 0.69 2.39 0.428
b-Blockers 0.87 0.66 1.14 0.309 0.81 0.57 1.13 0.215 0.91 0.62 1.33 0.612
MRA 0.90 0.69 1.16 0.410 1.01 0.73 1.40 0.949 1.25 0.88 1.77 0.210
LVEF, % 1.00 0.98 1.01 0.462 0.99 0.97 1.01 0.211 1.01 0.99 1.02 0.404
Creatinine, log lmol/L 2.20 1.72 2.82 <0.001 1.92 1.38 2.67 <0.001 1.93 1.34 2.76 <0.001
ACEIs indicates angiotensin-converting enzyme inhibitors; ARA, angiotensin receptor blockers; CABG, coronary artery bypass grafting; CRT-D, cardiac resynchronization therapy-
deﬁbrillation; HF, heart failure; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart Association;
QUAD, quadripolar left ventricular lead.
Results are expressed as hazard ratios and 95% conﬁdence intervals (CI) from Cox proportional hazards analyses.
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non-QUAD: 5 (0.90%; P=0.828) and 3 after 1 year (QUAD: 0);
non-QUAD: 3 (0.54%; P=0.214). No device-related infection or
subsequent extraction led to death.
Lead Design
Three LV lead families from 3 manufacturers were used,
namely, Quartet (n=189, St. Jude Medical, Sylmar, CA), Attain
Performa (n=87, Medtronic Inc, Minneapolis, MN), and Acuity
X4 (n=11, Boston Scientiﬁc, Marlborough, MA). Compared
with non-QUAD leads, Quartet leads (aHR: 0.36, 95% CI,
0.21–0.6; sample size: 560 non-QUAD and 189 Quartet leads)
as well as the Attain Performa leads (aHR: 0.11, 95% CI, 0.03–
0.45; sample size: 560 non-QUAD and 87 Attain Performa)
were associated with lower total mortality. Comparison of
Quartet (n=189) with Attain Performa (n=87) revealed no
difference in total mortality (Quartet HR: 3.06, 95% CI, 0.70–
13.38). Boston Scientiﬁc Acuity X4 leads were excluded from
these analysis because of the small numbers involved (n=11).
Discussion
In this study, we have compared clinical outcomes after CRT
using QUAD and non-QUAD, programmed to biventricular,
single-site LV pacing. Several ﬁndings have emerged. First,
QUAD was associated with a 68% lower total mortality.
Second, QUAD was associated with a marked reduction in
cardiac mortality (by 64%) and in HF hospitalization (by 38%).
Third, QUAD was associated with a lower mortality from pump
failure, while no differences emerged in sudden cardiac death.
Fourth, HF cause did not impact on the superior outcomes of
QUAD over non-QUAD. Fifth, QUAD was superior to non-
QUAD after both CRT-D and CRT-P. Sixth, no group differ-
ences emerged in implant complications, but QUAD was
associated with fewer re-interventions for LV lead
displacement or PNS. Seventh, re-interventions for LV
displacement or PNS predicted total mortality, cardiac
mortality, and HF hospitalization.
Mortality
A recent retrospective study comparing QUAD with bipolar
leads showed no difference in survival at 12 months (mean
follow-up 256 days for QUAD).15 In contrast, a US-wide study
based on data from device implant records and telemonitoring
showed that CRT-D using QUAD was associated with a better
survival than CRT-D using bipolar leads.13 Observational data
from 3 centers in the United Kingdom showed similar
ﬁndings.12
Our annualized total mortality rate for non-QUAD (10.9%) is
comparable to that found in randomized, controlled trials
using non-QUAD, which amounted to 9.7% in CARE-HF
(Cardiac Resynchronization Heart Failure)18 and 15% in
COMPANION (Comparison of Medical Therapy, Pacing and
Deﬁbrillation in heart failure)19,20 after CRT-P. In the CRT-D
arm of COMPANION, the annualized total mortality rate was
12%.20 In contrast, the annualized total mortality rate in the
present study was 3.6% with QUAD.
HF Hospitalization
This is the ﬁrst study to explore HF hospitalization after CRT
using QUAD. Survival free from cardiovascular hospitalization
at 1 and 2 years with QUAD was 94% and 91%, respectively.
Among the few studies to address the long-term effects of
CRT on HF hospitalizations in the non-QUAD LV lead era, van
Bommel et al found survival free from cardiovascular hospi-
talization at 1 and 2 years was 80% and 70%, respectively.21
The reasons for reduced HF hospitalizations with QUAD are
not entirely clear. Several cofounders, however, could
Table 4. Multivariable Analyses of Baseline Variables in Relation to Clinical Outcomes
Total Mortality Cardiac Mortality HF Hospitalization
HR 95% CI P Value HR 95% CI P Value HR 95% CI P Value
Lead type (QUAD) 0.32 0.20 0.52 <0.001 0.36 0.20 0.65 0.001 0.62 0.39 0.99 0.047
Sex, male 1.65 1.18 2.31 0.003 1.74 1.13 2.70 0.013    
Age, y 1.03 1.02 1.05 <0.001 1.02 1.00 1.03 0.043 1.03 1.01 1.05 0.001
NYHA class (IV) 1.89 1.25 2.86 0.003        
QRS duration, ms     0.99 0.99 1.00 0.019 0.99 0.98 0.99 <0.001
ACEIs/ARAs     0.64 0.42 0.99 0.044    
Creatinine, log lmol/L 1.68 1.25 2.25 0.001 1.50 1.04 2.16 0.030 1.91 1.30 2.80 0.001
Only variables with P<0.10 on univariable analyses were included in multivariable models. ACEI, angiotensin-converting enzyme inhibitors; ARA, angiotensin receptor blockers; HF, heart
failure; NYHA, New York Heart Association; QUAD, quadripolar left ventricular lead.
Results are expressed as hazard ratios and 95% conﬁdence intervals (CI) from Cox proportional hazards analyses.
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Figure 2. Clinical outcomes according to device and lead type. Kaplan–Meier survival curves for clinical outcomes according to device and
lead type. aHR indicates adjusted hazard ratio; C.I., conﬁdence interval; CRT-D, cardiac resynchronization therapy-deﬁbrillation; CRT-P,
cardiac resynchronization therapy-pacing; HF, heart failure; QUAD, quadripolar lead.
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potentially explain our ﬁndings. In the telemonitoring study of
Turakhia et al, potential confounders for a beneﬁt of QUAD
was limited to age, sex, remote monitoring enrollment, and
socioeconomic status.13 Behar et al did not adjust for NYHA
class, QRS duration, left ventricular ejection fraction, HF
medication, or comorbidities.12 In the present study, which
comprises a longer follow-up period, the survival advantage of
QUAD versus bipolar LV leads was observed after adjustment
for age, sex, device type (CRT-P or CRT-D), NYHA class, QRS
duration, QRS morphology, left ventricular ejection fraction,
HF cause, medication, or history of hypertension, coronary
artery bypass grafting, or diabetes mellitus.
Lower rates of LV lead re-interventions may also be
relevant. In this respect, we observed that no LV lead revision
led to death and that LV lead re-interventions were lower for
QUAD than for non-QUAD. On the other hand, LV lead re-
interventions were associated with an increased risk of total
mortality, cardiac mortality, and HF hospitalization. These
ﬁndings suggest that LV lead deactivation and the associated
re-intervention contributed to a higher risk of HF hospitaliza-
tion. This, however, does not explain the lower risk of total
mortality observed with QUAD. It would appear that the
survival beneﬁt of QUAD relates to the lead itself.
CRT-D and CRT-P
Previous studies on QUAD12,13 have exclusively focused on
CRT-D. We have shown better outcomes for QUAD after both
CRT-D and CRT-P. In fact, the magnitude of the survival
beneﬁt of QUAD over non-QUAD after CRT-P (by 84%) was
higher than after CRT-D (by 56%). While we should be careful
with overinterpreting the results of a retrospective study, such
marked differences raise the possibility that the beneﬁt of
QUAD is proportionally higher after CRT-P than after CRT-D. If
that is the case, we should reconsider the ﬁndings of
COMPANION, which was underpowered to compare CRT-D
and CRT-P. At the low event rates observed in the present
study, proof of superiority of CRT-D over CRT-P may require
much higher numbers of patients than those included in
COMPANION. Meta-analyses of CRT-D versus CRT-P may
need to be revisited in the QUAD era.
LV Lead Re-Interventions
In theMORE-CRT (MoreOptions AvailableWith aQuadripolar LV
Lead Provide In-Clinic Solutions to CRT Challenges) trial, 1074
patients undergoing CRT-D were randomized in 1:2 ratio to
bipolar leads or QUAD. Freedom from the composite end point
of intraoperative and postoperative LV lead–related events at
6 months was greater with QUAD than with bipolar leads
(83.0% versus 74.4%, P=0.0002), but this was because of
differences in the intraoperative rather than postoperative
events.10 In the present study, which involved a longer follow-up
period, QUADwas associatedwith a lower incidence of PNS and
LV lead displacement. This might be expected in view of the fact
that vector optimization almost invariably eliminates PNS in
patients who initially have PNS with QUAD.12
HF Cause
In the QUAD era, Forleo et al22 showed that the cause of
cardiomyopathy did not inﬂuence the LV reverse remodeling
response to CRT-D using QUAD. Similarly, Behar et al found
no interaction between HF cause and the survival beneﬁt of
CRT-D using QUAD, compared with bipolar leads.12 We have
also found that HF cause has no bearing on survival beneﬁt of
QUAD over non-QUAD. Importantly, however, the event rate
with QUAD is much lower than with non-QUAD. It is possible
that with QUAD, higher numbers of patients are needed to
show a HF cause-speciﬁc difference in outcomes after CRT.
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Figure 3. Mode of death according to lead type. Kaplan–Meier
survival curves for death from pump failure or sudden cardiac
death (SCD) according to lead type. aHR indicates adjusted
hazard ratio; C.I., conﬁdence interval; QUAD, quadripolar lead.
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Single-Site and Multipoint Pacing
In this study, multipoint pacing was not activated in any
patient, suggesting that the survival advantage of QUAD is
simply because of lead design or availability of multiple pacing
vector conﬁgurations. We should also consider that electrical
stimulation over a dipole in a QUAD could depolarize the
myocardium at the anodal pole if this has a comparatively low
threshold.23 We cannot determine whether anodal capture
(and effectively multipoint pacing) could account for some of
the observed effects of QUAD. These questions could not be
addressed in the present study.
Limitations
This study has the typical limitations of a single-center,
nonrandomized, retrospective study and therefore we cannot
discount the possible inﬂuence of unobserved variables. While
we adjusted for potential confounders, only randomization
could fully correct for their biological effects. In particular, we
should stress that, despite covariate adjustment, the better
Table 5. Implant-Related Complications and Re-Interventions.
All QUAD Non-QUAD P Value*
847 287 560
Implant-related complications, n (%)
Hematoma treated conservatively 23 (2.72) 10 (3.48) 14 (2.50) 0.390
Hematoma requiring evacuation 4 (0.47) 0 4 (0.71)
Pneumothorax treated conservatively 5 (0.59) 2 (0.70) 3 (0.54)
Pneumothorax requiring drainage 1 (0.12) 0 1 (0.18)
Perforation by RV lead 2 (0.24) 1 (0.35) 1 (0.18)
Coronary sinus dissection† 5 (0.59) 4 (1.39) 3 (0.54)
Subclavian artery aneurysm 1 (0.12) 1 (0.35) 0
Arrhythmia requiring cardioversion 1 (0.12) 1 (0.35) 0
Anemia postprocedure 1 (0.12) 0 1 (0.18)
Pulmonary edema 1 (0.12) 0 1 (0.18)
Total, n (%) 44 (5.19) 19 (6.62) 28 (5.00)
Extractions for infection
Within 1 y 8 (1.43) 3 (1.05) 5 (0.89) 0.297
After 1 y 3 (0.53) 0 3 (0.54)
Total, n (%) 11 (1.96) 3 (1.05) 8 (1.43)
LV lead re-interventions
LV lead displacement 34 (4.01) 6 (2.09) 28 (5.0) 0.007
Phrenic nerve stimulation 19 (2.24) 3 (1.05) 16 (2.86)
Total 53 (6.26) 9 (3.14) 44 (7.86)
RV indicates right ventricular.
*Refers to v2 tests of quadripolar (QUAD) compared with non-QUAD left ventricular (LV) leads.
†No coronary sinus dissections required re-interventions.
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Figure 4. Reinterventions for left ventricular lead displacement
or phrenic nerve stimulation. Kaplan–Meier survival curves of re-
interventions for left ventricular (LV) lead displacement or phrenic
nerve stimulation (PNS) after device implantation using quadripo-
lar (QUAD) or non-QUAD leads. aHR indicates adjusted hazard
ratio.
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outcomes observed with QUAD might be because, at least in
part, of different patient characteristics towards the end of
the recruitment period, rather than primarily or uniquely to the
utilization of QUAD. The greater proportion of patients in
NYHA class I and II and in sinus rhythm as well as higher
uptake of angiotensin-converting enzyme inhibitors/an-
giotensin receptor blockers and b-blockers may still con-
tribute to better outcomes with QUAD. Moreover, we cannot
exclude the possibility that the time interval from actual LV
lead displacement (deactivation) to re-intervention may have
adversely inﬂuenced outcomes. As we did not use telemon-
itoring, we cannot quantify the duration of LV lead deactiva-
tion before re-intervention. A further possibility is that
allowing programming over a wider range of vectors, QUAD
could have converted nonresponders to responders.24 Unfor-
tunately, the present study does not address vector locations
or how vector conﬁgurations changed during follow-up. It is
hoped that ongoing prospective studies25 may shed further
light on this issue. We did not collect data as on Q-LV as an
aid for targeting LV lead positions, but it is possible that this
approach could inﬂuence outcomes.
Conclusions
In this study of real-world clinical practice, we have shown
that CRT using QUAD, programmed to biventricular, single-
site LV pacing, was associated with a dramatic reduction in
total mortality, cardiac mortality, and HF hospitalization,
compared with non-QUAD. These ﬁndings emerged after both
CRT-D and CRT-P, after adjustment for HF etiology and other
potential confounders. The remarkably low event rate
observed with QUAD in this study has implications for clinical
practice and the design of future CRT trials.
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